Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial
Johan Maertens(KU Leuven), Galia Rahav(Tel Aviv University), Dong‐Gun Lee(Catholic University of Korea), Alfredo Ponce‐de‐León(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Isabel Cristina Ramírez Sánchez(Hospital Pablo Tobon Uribe), Н Н Климко(North-Western State Medical University named after I.I. Mechnikov), Anne Sonet(UCLouvain), Shariq Haider(Juravinski Hospital), Juan D. Vélez(Fundación Valle del Lili), Issam Raad(The University of Texas MD Anderson Cancer Center), Liang‐Piu Koh(National University Cancer Institute, Singapore), Meinolf Karthaus(München Klinik Neuperlach), Jianying Zhou(First Affiliated Hospital Zhejiang University), Ronen Ben‐Ami(Tel Aviv Sourasky Medical Center), Mary Motyl(Merck & Co., Inc., Rahway, NJ, USA (United States)), Seongah Han(Merck & Co., Inc., Rahway, NJ, USA (United States)), Anjana Grandhi(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hetty Waskin(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 272Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis